Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer

NCT05838729 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Head Neck Cancer
Intratumoral Injection

Interventions

DRUG: RiMO-301

Sponsor

Coordination Pharmaceuticals, Inc.

Collaborators

[object Object]